Skip to main content
. 2024 Jul 16;210(11):1358–1369. doi: 10.1164/rccm.202401-0165OC

Figure 1.


Figure 1.

Observed pyrazinamide plasma concentration with respect to time after dose. Circles represent individual samples, and solid lines represent medians. Data are stratified by treatment regimens (left, 6-month control; middle, 4-month rifapentine-containing regimen; right, 4-month rifapentine–moxifloxacin–containing regimen) and by dose (green, 1,000 mg; purple, 1,500 mg; yellow, 2,000 mg).